In this issue:
Rectal cancer on the rise in younger patients
Rectal cancer patients <50 lack a survival benefit from NCCN guideline
Addition of oxaliplatin benefits patients <60 years
In mCRC
Similar survival in left-sided vs rectal tumours
Modest PFS benefit with regorafenib
Significant survival benefit with cetuximab
Maintenance with single-agent cetuximab
No survival benefit with nintedanib
Panitumumab benefits left-sided RAS wild-type
Limited benefit of pelareorep
Please login below to download this issue (PDF)